- Home
- BCAL vs DSGN Comparison
BCAL vs DSGN Comparison
Compare BCAL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAL | DSGN |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.3M | 579.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCAL | DSGN |
|---|---|---|
| Price | $18.36 | $10.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.50 | $15.00 |
| AVG Volume (30 Days) | ★ 187.9K | 176.1K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 26.05 |
| EPS | ★ 1.42 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.35 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.88 | $2.62 |
| 52 Week High | $20.47 | $11.14 |
Technical Indicators
Market Signals| Indicator | BCAL | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 50.37 |
| Support Level | $17.80 | $9.62 |
| Resistance Level | $19.31 | N/A |
| Average True Range (ATR) | 0.44 | 0.48 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 39.17 | 36.46 |
Price Performance
Historical ComparisonAbout BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.